INTRA-CELLULAR THERAPIES, INC. — Lobbying Disclosure | Poliscope

INTRA-CELLULAR THERAPIES, INC.

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$605K

Filings

Firms Hired

Active Period

2004–2025

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2025	$80,000	7	2
2024	$210,000	8	2
2023	$210,000	9	2
2022	$105,000	9	2
2005	—	2	1
2004	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
INTRA-CELLULAR THERAPIES, INC.	$605,000	18
DLA PIPER LLP (US)	—	15
DAVIDOFF HUTCHER & CITRON, LLP	—	5

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	30
SENATE	29
Centers For Medicare and Medicaid Services (CMS)	7

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	28
Medicare/Medicaid	Medicare/Medicaid	17
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	9
Budget/Appropriations	Budget/Appropriations	3
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	2
Alcohol and Drug Abuse	Alcohol and Drug Abuse	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 5376119th Congress

Impacts and Outcomes for Health Career Training Act

2025 · fourth_quarter · Firm: DLA PIPER LLP (US)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health. H.R. 5376, Impacts and Outcomes for Health Career Training Act.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5376

H.R. 5376119th Congress

Impacts and Outcomes for Health Career Training Act

2025 · third_quarter · Firm: DLA PIPER LLP (US)

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health. H.R. 5376, Impacts and Outcomes for Health Career Training Act.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5376

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · second_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1492 - EPIC Act: Provisions regarding harmonizing small and large molecule period in the Inflation Reduction Act.

Client expense: $10,000 · Firm income: —

Matched citations: H.R. 1492

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · first_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1492 - EPIC Act: Provisions regarding harmonizing small and large molecule period in the Inflation Reduction Act.

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 1492

Show 21 more cited filings

H.R. 1990119th Congress

American Innovation and R&D Competitiveness Act of 2025

2025 · first_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1990 - American Innovation and R&D Competitiveness Act: Provisions regarding Section 174 research and development tax credit amortization.

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 1990

H.R. 3938118th Congress

Build It in America Act

2024 · fourth_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 3938: Build it in America Act - Provisions regarding research and development tax credit amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax credit amortization.

Client expense: $40,000 · Firm income: —

Matched citations: HR 3938

H.R. 7174118th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2024 · fourth_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception. H.R. 7174: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - Provisions regarding reforms to the Inflation Reduction Act (IRA) MFP negotiation process.

Client expense: $40,000 · Firm income: —

Matched citations: H.R. 7174

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · fourth_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $40,000 · Firm income: —

Matched citations: S. 1339

S. 2973118th Congress

Modernizing and Ensuring PBM Accountability Act

2024 · fourth_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $40,000 · Firm income: —

Matched citations: S. 2973

S. 866118th Congress

American Innovation and Jobs Act

2024 · fourth_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 3938: Build it in America Act - Provisions regarding research and development tax credit amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax credit amortization.

Client expense: $40,000 · Firm income: —

Matched citations: S. 866

H.R. 2630118th Congress

Safe Step Act

2024 · third_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $50,000 · Firm income: —

Matched citations: HR 2630

H.R. 3938118th Congress

Build It in America Act

2024 · third_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 3938: Build it in America Act - Provisions regarding research and development tax amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax amortization.

Client expense: $50,000 · Firm income: —

Matched citations: HR 3938

H.R. 7174118th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2024 · third_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception. H.R. 7174: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - Provisions regarding reforms to the Inflation Reduction Act (IRA) MFP negotiation process. Part D 6 protected classes policy. Medicaid Drug Rebate Program Rule - Provisions regarding "stacking" of rebates and discounts.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 7174

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · third_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $50,000 · Firm income: —

Matched citations: S. 1339

S. 2973118th Congress

Modernizing and Ensuring PBM Accountability Act

2024 · third_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $50,000 · Firm income: —

Matched citations: S. 2973

S. 652118th Congress

Safe Step Act

2024 · third_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $50,000 · Firm income: —

Matched citations: S. 652

S. 866118th Congress

American Innovation and Jobs Act

2024 · third_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 3938: Build it in America Act - Provisions regarding research and development tax amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax amortization.

Client expense: $50,000 · Firm income: —

Matched citations: S. 866

H.R. 2630118th Congress

Safe Step Act

2024 · second_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $50,000 · Firm income: —

Matched citations: HR 2630

H.R. 3938118th Congress

Build It in America Act

2024 · second_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 3938: Build it in America Act - Provisions regarding research and development tax amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax amortization.

Client expense: $50,000 · Firm income: —

Matched citations: HR 3938

H.R. 7174118th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2024 · second_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception. H.R. 7174: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - Provisions regarding reforms to the Inflation Reduction Act (IRA). Part D 6 protected classes policy. Medicaid Drug Rebate Program Rule - Provisions regarding "stacking" of rebates and discounts.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 7174

S. 1339118th Congress

Pharmacy Benefit Manager Reform Act

2024 · second_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $50,000 · Firm income: —

Matched citations: S. 1339

S. 2973118th Congress

Modernizing and Ensuring PBM Accountability Act

2024 · second_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $50,000 · Firm income: —

Matched citations: S. 2973

S. 652118th Congress

Safe Step Act

2024 · second_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $50,000 · Firm income: —

Matched citations: S. 652

S. 866118th Congress

American Innovation and Jobs Act

2024 · second_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 3938: Build it in America Act - Provisions regarding research and development tax amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax amortization.

Client expense: $50,000 · Firm income: —

Matched citations: S. 866

H.R. 2630118th Congress

Safe Step Act

2024 · first_quarter · Firm: INTRA-CELLULAR THERAPIES, INC.

Open original LDA filing ↗

Cited source text and reported amounts

HR 2630/S. 652: Safe Step Act - Provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

Client expense: $70,000 · Firm income: —

Matched citations: HR 2630

Source: Senate LDA